



ASX/MEDIA RELEASE

14 December 2004

**BONE MEDICAL ANNOUNCES PROMINENT NEW MEMBERS TO
SCIENTIFIC ADVISORY COMMITTEE**

Biopharmaceutical development company Bone Medical Limited (**ASX: BNE**) is pleased to announce the appointment of Professor Peter Brooks and Professor Philip Sambrook to its Scientific Advisory Committee.

Professor Peter Brooks is the Executive Dean of Health Sciences at the University of Queensland and Chairman of the “Bone & Joint Decade” National Action Network. Professor Brooks is internationally recognised as an expert in the treatment and epidemiology of rheumatic diseases.

Professor Philip Sambrook is the Florence & Cope Professor of Rheumatology at the University of Sydney and the Director of the Institute for Bone & Joint Research at Sydney’s Royal North Shore Hospital. His particular research interests include the epidemiology, genetics and treatment of osteoporosis and osteoarthritis. Professor Sambrook is also a member of several international Scientific Editorial Boards, Vice President of the Asia Pacific Osteoporosis Foundation and a member of the Osteoporosis Australia Board.

The Chairman of Bone Medical’s Scientific Advisory Committee Mr Chris Bilkey said Professors Brooks and Sambrook are two of the most influential and experienced clinicians in the area of musculoskeletal disease in Australia and have exceptional international reputations in this therapeutic area.

“Their addition to Bone Medical’s Scientific Advisory Committee will provide the company with a tremendous depth of knowledge and first hand clinical experience that will be invaluable in planning effective clinical pathways,” said Mr Bilkey.

-ENDS-

For more information about Bone Medical Limited, please contact:

Dr Jim Phillips
Chief Executive Officer
+33 450734761

John Fitzgerald
Chief Operating Officer
+61 (0)419 600 375

Ann M. Nahajski
Porter Novelli
+61 8 9386 1233

Or visit: www.bonemedical.com

About Bone Medical Limited

Bone Medical Limited is an international biopharmaceutical development company positioned to exploit the growing market in the treatment of bone disease particularly in osteoporosis and arthritis. Bone has a portfolio of biopharmaceutical development projects for the treatment of bone disease including,

Osteoporosis

- oral calcitonin BN002
- oral parathyroid hormone BN003
- combination therapy BN004

Arthritis

- TNF regulators BN006
- bone cell regulators BN005/BN008
- joint protection & collagen tolerance BN007